Boston Scientific
BSX
$50.37
+2.03%
Boston Scientific Corp. is a global medical technology company that develops and manufactures minimally invasive medical devices used in a range of interventional procedures, including cardiology, rhythm management, endoscopy, urology, and neuromodulation. As a leading player in the medical devices industry, Boston Scientific differentiates itself through its broad and diversified product portfolio, strong R&D pipeline, and global commercial footprint, with foreign sales accounting for roughly 36% of total revenue. The current investor narrative centers on the company's strategic pivot into high-growth markets like TAVR (transcatheter aortic valve replacement) through a $1.5 billion investment in MiRus, which has captured Wall Street's attention, while the stock has faced significant volatility due to underwhelming clinical trial results and broader market sell-offs, creating a debate about whether the recent decline presents a buying opportunity or signals deeper challenges.…
BSX
Boston Scientific
$50.37
Related headlines
Investment Opinion: Should I buy BSX Today?
Rating: Buy. The thesis is that Boston Scientific's strong revenue growth, improving profitability, and strategic TAVR investment are not reflected in the current price, which is near its 52-week low. The analyst consensus is 'buy' with an average target of $62.69, implying 20.9% upside. Supporting evidence includes: 11.58% YoY revenue growth in Q1 2026, gross margin of 69.0%, operating margin of 19.8%, and forward PE of 15.07x, which is reasonable given estimated EPS growth to $4.70. The PEG ratio of 0.88 suggests undervaluation relative to growth. Risks: The biggest risks are continued clinical trial failures, competitive pressure in TAVR, and macro-driven market sell-offs. If the stock fails to hold above its 52-week low of $42.20, the thesis would be invalidated. This Buy would upgrade to a Strong Buy if the stock drops below $45 with stable fundamentals, or downgrade to Hold if revenue growth falls below 8% or clinical setbacks recur. Overall, the stock appears undervalued relative to its growth prospects and analyst targets.
Sign up to view all
BSX 12-Month Price Forecast
The AI assessment leans bullish due to the strong fundamental growth and attractive forward valuation. The stock's severe decline appears overdone relative to its earnings power, and the analyst community remains supportive. However, the medium confidence reflects the technical downtrend and clinical trial risks. If the company delivers on its forward EPS estimates and TAVR progress, the stock could re-rate significantly. Key developments to watch include Q2 earnings (due late July) and any updates on MiRus integration. A downgrade to neutral would occur if revenue growth slips below 8% or if the stock breaks below $42.20.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $62.69 and implied upside of +24.5% versus the current price.
Average Target
$62.69
0 analysts
Implied Upside
+24.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $94
Analyst target range
Boston Scientific is covered by 29 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.58 (where 1 is strong buy and 5 is sell), indicating a bullish sentiment. The average target price is $62.69, which implies an upside of approximately 20.9% from the current price of $51.83. The distribution of ratings is not explicitly provided, but the low mean score suggests a majority of analysts rate the stock as a buy or outperform, with no sell ratings indicated. This bullish consensus is supported by recent institutional actions, as firms like Mizuho, RBC Capital, and Needham have reaffirmed their outperform or buy ratings in July 2026, reflecting confidence in the company's long-term growth strategy.
Bulls vs Bears: BSX Investment Factors
Boston Scientific presents a classic value-versus-value-trap debate. On the bull side, the company boasts robust double-digit revenue growth, strong margins, and a strategic TAVR investment that could drive future growth. The analyst consensus is firmly bullish, with a 20.9% upside to the average target. On the bear side, the stock has been in a severe downtrend, down 50% over the past year, with disappointing clinical results and a high trailing PE. The single most important tension is whether the recent decline is an overreaction to temporary setbacks or a reflection of fundamental deterioration. If the company can maintain its growth trajectory and successfully integrate MiRus, the stock is likely undervalued; if growth decelerates or pipeline setbacks continue, further downside is possible. Currently, the evidence slightly favors the bulls given the strong fundamentals and analyst support, but the technical weakness warrants caution.
Bullish
- Double-digit revenue growth: Q1 2026 revenue grew 11.58% YoY to $5.203B, with consistent sequential growth from $5.061B in Q2 2025 to $5.286B in Q4 2025. This demonstrates strong demand across its cardiovascular and MedSurg portfolios.
- Analyst consensus is bullish: 29 analysts rate BSX a 'buy' with a mean score of 1.58 (1=strong buy, 5=sell). The average target price of $62.69 implies ~20.9% upside from the current price of $51.83, with a high target of $94.
- Strategic TAVR investment: The $1.5B investment in MiRus provides a low-risk entry into the high-growth TAVR market, which could become a significant growth driver. Wall Street has taken notice, with firms like Mizuho and RBC reaffirming buy ratings in July 2026.
- Strong profitability metrics: Gross margin is 69.0%, operating margin is 19.8%, and net margin is 14.4% (TTM). Q1 2026 net income of $1.337B was up 98% YoY, reflecting strong operational leverage.
Bearish
- Severe stock price decline: BSX is down 50.24% over the past year, trading near its 52-week low of $42.20. The stock has lost over half its value, reflecting significant investor pessimism and a broken downtrend.
- Underwhelming clinical trial results: In March 2026, the stock fell sharply after delivering underwhelming trial results, which raised doubts about pipeline prospects. This event triggered a sell-off that contributed to the stock's decline.
- High trailing valuation: Trailing PE is 48.65x, well above the market average, indicating the market was pricing in high growth expectations that have not been met. Even with forward PE of 15x, the stock is not cheap on current earnings.
- Negative relative strength: BSX has underperformed the S&P 500 by 70.6% over the past year (relative strength -70.6%). Over 6 months, it is down 30.6% while the market is up 13.9%, showing persistent weakness.
BSX Technical Analysis
Boston Scientific's stock is in a pronounced downtrend over the past year, with a 1-year price change of -50.24%, reflecting a severe erosion of value. The current price of $51.83 sits at approximately 14.5% of its 52-week range (calculated as (51.83 - 42.2) / (109.5 - 42.2) = 14.2%), indicating the stock is trading near its 52-week low of $42.20 and far below the high of $109.50. This positioning near the lows suggests the market is pricing in significant pessimism, but it could also represent a potential value opportunity if the company's fundamentals stabilize, though the falling knife risk remains elevated.
Beta
0.57
0.57x market volatility
Max Drawdown
-60.6%
Largest decline past year
52-Week Range
$42-$110
Price range past year
Annual Return
-52.1%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | +17.2% | +2.5% |
| 3m | -12.8% | +2.7% |
| 6m | -32.5% | +11.1% |
| 1y | -52.1% | +20.5% |
| ytd | -46.8% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Boston Scientific's revenue trajectory has been robust, with the most recent quarter (Q1 2026) reporting revenue of $5.203 billion, a year-over-year growth of 11.58%. This growth is consistent with the prior quarters, as Q4 2025 revenue was $5.286 billion, Q3 2025 was $5.065 billion, and Q2 2025 was $5.061 billion, showing a steady upward trend. The growth is driven by strong performance in the Cardiovascular segment, which generated $3.493 billion in revenue, while MedSurg contributed $1.814 billion, indicating that the cardiovascular portfolio is the primary growth engine. The company's ability to sustain double-digit growth in a mature medical devices market underscores its competitive strength and successful product launches, though investors should monitor whether this pace can be maintained given the competitive landscape.
Quarterly Revenue
$5.2B
2026-03
Revenue YoY Growth
+11.6%
YoY Comparison
Gross Margin
69.4%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Given that Boston Scientific has positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 48.65x, while the forward PE is 15.07x, indicating that the market expects a significant earnings increase in the next year, which is consistent with the estimated EPS growth. The gap between trailing and forward PE suggests that the market is pricing in a substantial earnings recovery, likely driven by margin expansion and continued revenue growth. However, the trailing PE is elevated compared to the broader market, reflecting the premium investors place on the company's growth prospects, but the forward PE appears more reasonable if the earnings estimates are met.
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~88x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks: Boston Scientific carries a debt-to-equity ratio of 0.51, indicating moderate leverage. The company's trailing PE of 48.65x is elevated, and if earnings growth fails to meet the forward estimates (EPS of $4.70), the stock could face de-rating. Free cash flow is positive at $3.44B TTM, but the $1.5B MiRus investment increases capital allocation risk. Revenue concentration in cardiovascular (67% of Q1 revenue) exposes the company to segment-specific headwinds. The lack of a dividend (payout ratio 0%) means investors rely solely on capital appreciation, which has been negative over the past year.
FAQ
The key risks are: 1) Clinical trial failures, as seen in March 2026, which can cause sharp sell-offs. 2) Competitive pressure in the TAVR market from established players like Edwards Lifesciences and Medtronic. 3) Macroeconomic risks, as the stock has a beta of 0.566, but the market sell-off in March-April 2026 hit BSX hard. 4) Financial risks from the $1.5B MiRus investment and debt-to-equity of 0.51. The most severe risk is a further decline to the 52-week low of $42.20, which would represent a -18.6% loss from the current price. Investors should monitor clinical data and competitive developments closely.
The 12-month forecast is based on three scenarios: Bull case (30% probability) targets $70-$94, driven by successful TAVR integration and strong earnings. Base case (50% probability) targets $55-$65, aligning with the analyst average of $62.69. Bear case (20% probability) targets $42-$48, if clinical setbacks or market downturns occur. The most likely scenario is the base case, assuming the company maintains its growth trajectory. The stock is expected to recover from its current oversold levels, but the pace will depend on earnings and TAVR progress.
BSX appears undervalued on a forward basis, with a forward PE of 15.07x, which is reasonable given the estimated EPS growth to $4.70. The PEG ratio of 0.88 suggests the stock is trading below its growth rate. However, the trailing PE of 48.65x is high, reflecting the market's prior expectations. Compared to peers, the forward PE is in line with the medical devices sector, but the stock's recent decline has made it more attractive. The market is pricing in a significant earnings recovery, and if that materializes, the stock is undervalued. If earnings disappoint, the stock could be fairly valued or even overvalued.
BSX is a good buy for investors with a long-term horizon and a tolerance for volatility. The stock is down 50% over the past year, but the company's fundamentals remain strong, with 11.58% revenue growth and a forward PE of 15x. Analyst consensus is 'buy' with an average target of $62.69, implying 20.9% upside. However, the stock is near its 52-week low, and there are risks from clinical trial failures and competitive pressures. For investors who believe in the TAVR opportunity and the company's growth trajectory, the current price offers an attractive entry point. For those with a short-term focus, the technical downtrend suggests waiting for a stabilization signal.
BSX is more suitable for long-term investment due to its growth stage and volatility. The stock has a beta of 0.566, indicating lower volatility than the market, but it has experienced a 50% drawdown over the past year, showing that short-term trading is risky. The company's strong revenue growth and strategic investments in TAVR provide a foundation for long-term appreciation. There is no dividend, so investors rely on capital gains. A minimum holding period of 3-5 years is recommended to allow the TAVR opportunity to materialize and for the stock to recover from its current lows. Short-term traders may find opportunities in oversold bounces, but the trend is currently down.